H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) and set a price target of $80.00. The analyst based the optimistic rating on the company’s gene editing pipeline, especially with their base editing therapies.

Is Beam Therapeutics Inc. (BEAM) the Best Gene-Editing Stock to Buy?

A patient undergoing MRI scanning to effectively diagnose Liver Diseases.

Beam Therapeutics Inc. (NASDAQ: BEAM) is making considerable progress in several areas, including BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, and the ESCAPE platform for non-genotoxic conditioning. This progress has generated considerable investor interest in Beam Therapeutics Inc. (NASDAQ:BEAM), as it reflects the company’s potential in both ex vivo and in vivo clinical programs, with commercialization readiness and a clear regulatory strategy.

The analyst further reasoned that upcoming milestones are anticipated to drive additional value for Beam Therapeutics Inc. (NASDAQ:BEAM), including the initiation of a Phase 1 trial for BEAM-103 and the completion of patient dosing in the BEACON trial for BEAM-10. The company has established proof-of-concept and a fully integrated manufacturing platform, which, according to the analyst, fully equips it to deliver innovative genetic medications and supports the Buy rating.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that develops precision genetic medicines through base editing, a technology that allows efficient and predictable single-base changes at targeted genomic sequences. The company’s lead programs focus on sickle cell disease and alpha-1 antitrypsin deficiency.

Beam Therapeutics Inc. (NASDAQ:BEAM) is advancing programs in other genetic diseases as well, along with oncology and immunology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301, and BEAM-201.

While we acknowledge the potential of BEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.